Please provide your email address to receive an email when new articles are posted on . Apremilast led to better clinical outcomes in early oligoarticular PsA vs. placebo at 16 weeks. Safety was ...

Oral ulcers, the hallmark of Behçet’s syndrome, can be resistant to conventional treatment; therefore, alternative agents are needed. Apremilast is an oral phosphodiesterase-4 inhibitor that modulates ...

SAN FRANCISCO, CA—Longer-term efficacy and safety data from the Phase 3 PALACE 1 study have confirmed that apremilast at 20mg and 30mg twice-daily doses continues to demonstrate “sustained and ...

Credit: Getty Images. The sNDA is supported by data from the multicenter, double-blind, placebo-controlled phase 3 ADVANCE trial. The Food and Drug Administration (FDA) has accepted for review the ...

WASHINGTON — In the phase 3 PALACE-1 trial, the investigational agent apremilast led to significant improvement in the signs and symptoms of psoriatic arthritis (PsA) in patients who failed to respond ...

Researchers conducted a multicenter observational study across three major US academic medical centers with registries of patients with rheumatic immune-related adverse events to assess the ...

Improvements in disease severity and quality of life measures among adults with psoriasis who are receiving apremilast was independent of genital psoriasis involvement. Apremilast improves disease ...

Pediatric patients with plaque psoriasis receiving apremilast vs placebo experienced significantly greater improvements in global disease activity and skin involvement. Treatment with apremilast was ...

As per IQVIATM sales data covering the 12-month period up to August 2023, the market for Otezla® tablets in these dosage forms achieved annual sales of around $3.7 billion. Mumbai: Glenmark ...

The small-molecule phosphodiesterase 4 inhibitor apremilast modulates cytokines that are up-regulated in Behçet’s syndrome. In a phase 2 trial involving patients with Behçet’s syndrome, apremilast ...

Phosphodiesterase (PDE) 4 inhibitors have been reported to suppress the progression of dermal fibrosis in patients with systemic sclerosis (SSc); however, the precise mechanisms remain to be ...

Reviewers report that the dossiers submitted regarding the use of Apremilast for psoriasis contained neither data from studies of direct comparisons nor indirect comparisons. The manufacturer itself ...